Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
50.46 GBX | +0.92% | +8.75% | +43.97% |
11:58am | Renold gets GBP11 million contract with Royal Canadian Navy | AN |
08:48am | GSK ups outlook; Next first-quarter beats forecast | AN |
Valuation
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 60.41 | 19.54 | 48.69 | 44.65 | 53.06 | 104.6 | - | - |
Enterprise Value (EV) 1 | 90.41 | 56.14 | 48.69 | 58.45 | 82.86 | 139.3 | 134.2 | 133.9 |
P/E ratio | 8.38 x | 5.78 x | - | 4.66 x | 5 x | 6.45 x | 6.67 x | 6.58 x |
Yield | - | - | - | - | - | - | 0.8% | - |
Capitalization / Revenue | 0.3 x | 0.1 x | 0.29 x | 0.23 x | 0.21 x | 0.43 x | 0.43 x | 0.42 x |
EV / Revenue | 0.45 x | 0.3 x | 0.29 x | 0.3 x | 0.34 x | 0.58 x | 0.55 x | 0.54 x |
EV / EBITDA | 3.75 x | 2.62 x | 2.28 x | 2.37 x | 2.29 x | 3.47 x | 3.23 x | 3.2 x |
EV / FCF | -17.4 x | 33 x | - | 4.68 x | 9.98 x | 7.37 x | 10.2 x | 10.1 x |
FCF Yield | -5.75% | 3.03% | - | 21.4% | 10% | 13.6% | 9.84% | 9.86% |
Price to Book | 37.7 x | - | - | 7.59 x | 1.35 x | 1.98 x | 1.5 x | - |
Nbr of stocks (in thousands) | 225,418 | 225,418 | 225,418 | 217,795 | 208,060 | 209,153 | - | - |
Reference price 2 | 0.2680 | 0.0867 | 0.2160 | 0.2050 | 0.2550 | 0.5000 | 0.5000 | 0.5000 |
Announcement Date | 5/28/19 | 6/16/20 | 7/16/21 | 7/13/22 | 7/12/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 202.4 | 189.4 | 165.3 | 195.2 | 247.1 | 241.2 | 243.1 | 248 |
EBITDA 1 | 24.1 | 21.4 | 21.4 | 24.7 | 36.2 | 40.2 | 41.5 | 41.8 |
EBIT 1 | 16.4 | 13.4 | - | 15.3 | 24.3 | 29.1 | 29.75 | 30.8 |
Operating Margin | 8.1% | 7.07% | - | 7.84% | 9.83% | 12.06% | 12.24% | 12.42% |
Earnings before Tax (EBT) 1 | 11.2 | 4.9 | - | 12.4 | 17.3 | 22.55 | 21.7 | 23 |
Net income 1 | 7.7 | 1.8 | - | 10.2 | 11.8 | 16.55 | 15.05 | 15.8 |
Net margin | 3.8% | 0.95% | - | 5.23% | 4.78% | 6.86% | 6.19% | 6.37% |
EPS 2 | 0.0320 | 0.0150 | - | 0.0440 | 0.0510 | 0.0775 | 0.0750 | 0.0760 |
Free Cash Flow 1 | -5.2 | 1.7 | - | 12.5 | 8.3 | 18.9 | 13.2 | 13.2 |
FCF margin | -2.57% | 0.9% | - | 6.4% | 3.36% | 7.84% | 5.43% | 5.32% |
FCF Conversion (EBITDA) | - | 7.94% | - | 50.61% | 22.93% | 47.01% | 31.81% | 31.58% |
FCF Conversion (Net income) | - | 94.44% | - | 122.55% | 70.34% | 114.2% | 87.71% | 83.54% |
Dividend per Share 2 | - | - | - | - | - | - | 0.004000 | - |
Announcement Date | 5/28/19 | 6/16/20 | 7/16/21 | 7/13/22 | 7/12/23 | - | - | - |
Balance Sheet Analysis
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | 30 | 36.6 | - | 13.8 | 29.8 | 34.8 | 29.6 | 29.3 |
Net Cash position 1 | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 1.245 x | 1.71 x | - | 0.5587 x | 0.8232 x | 0.8644 x | 0.7133 x | 0.701 x |
Free Cash Flow 1 | -5.2 | 1.7 | - | 12.5 | 8.3 | 18.9 | 13.2 | 13.2 |
ROE (net income / shareholders' equity) | 837% | - | - | - | 58.6% | 29.8% | 23.3% | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | 0.0100 | - | - | 0.0300 | 0.1900 | 0.2500 | 0.3300 | - |
Cash Flow per Share 2 | 0.0400 | 0.0500 | 0.1200 | 0.1000 | - | 0.1300 | 0.1200 | 0.1100 |
Capex 1 | 10.7 | 9.2 | - | 5.3 | 8.4 | 10.5 | 10.5 | 10.5 |
Capex / Sales | 5.29% | 4.86% | - | 2.72% | 3.4% | 4.35% | 4.3% | 4.23% |
Announcement Date | 5/28/19 | 6/16/20 | 7/16/21 | 7/13/22 | 7/12/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+43.22% | 131M | |
+12.62% | 82.74B | |
+18.28% | 69.97B | |
+20.66% | 37.66B | |
+14.29% | 31.6B | |
+12.35% | 27.79B | |
+2.23% | 26.5B | |
+2.11% | 25.43B | |
+16.57% | 24.64B | |
+17.57% | 25.66B |
- Stock Market
- Equities
- RNO Stock
- Financials Renold plc